Lupin has said that its US arm Gavis has got the approval from the US health regulator for marketing Hydrocodone Bitartrate and Acetaminophen tablets which is a pain relieving drug, in the American market.

Lupin has said in a statement that Gavis Pharmaceuticals, a subsidiary of the company, has received final approval for its Hydrocodone Bitartrate and Acetaminophen tablets from the US Food and Drug Administration (USFDA).

According to IMS MAT sales data, Hydrocodone Bitartrate and Acetaminophen tablets had sales of USD 89.6 million in the US market.

Read EquityPandit’s Technical Analysis on Nifty Pharma